

## Synthesis of Statine and Its Analogues

Hiroaki YANAGISAWA,\* Takuro KANAZAKI, and Takahide NISHI

Chemical Research Laboratories, Sankyo Co., Ltd., Hiromachi,  
Shinagawa-ku, Tokyo 140

Statine, (3S,4S)-4-amino-3-hydroxy-6-methylheptanoic acid, and its analogues were prepared from 5,6-anhydro-3-deoxy-1,2-O-isopropylidene-D-glucofuranose. The key step is the stereospecific reaction of the epoxy sugar with the Grignard reagent.

The unusual  $\gamma$ -amino acid statine 1 is a component of the general aspartyl protease inhibitor pepstatin<sup>1)</sup> and plays an important role in binding with enzyme as a transition state or tetrahedral intermediate analogue of the scissile dipeptide unit of a substrate.<sup>2)</sup> The inhibitor of renin, the aspartyl protease which cleaves angiotensinogen to begin the cascade of the renin-angiotensin-aldosterone pressor system, has been expected to be an antihypertensive agent. Since the renin inhibitor having the statine unit had been shown to have a potent inhibitory activity,<sup>3)</sup> many statine analogues have been reported. For example, replacement of the isopropyl group in 1 by the cyclohexyl<sup>4)</sup> or 1,3-dithiolan-2-yl<sup>5)</sup> groups enhances the inhibitory activity and the inhibitors possessing homostatine, monomethylene extended statine, and its analogues<sup>6,7)</sup> have potent activity. Several stereospecific syntheses of 1 and its analogues have been demonstrated<sup>8)</sup> but there has been only one<sup>9)</sup> which employed sugar as a starting material where Grignard reaction of the pentodialdofuranose derivative with isopropylmagnesium bromide was the key step.

In this paper we describe the stereospecific synthesis of 1 and its





Fig. 1.

analogues shown in Figure 1 based upon Grignard reaction of the epoxy sugar 2<sup>10)</sup> derived from 1,2,5,6-di-O-isopropylidene-D-glucofuranose.

The synthesis of 1 and the analogues 9b-f modified at the isopropyl moiety of 1 is shown in Scheme 1. The epoxy sugar 2 was allowed to react with the Grignard reagents  $R^1MgBr$  in the presence of cuprous iodide to give the alcohols 3a-f. Mesylation of 3a-f followed by treatment with sodium azide gave the azido sugars 5a-f. In the case of the phenethyl derivative ( $R^1=Ph$ ), demethylsulfonyloxylation occurred and the 5,6-dehydrosugar was obtained with the azido sugar in a ratio of 1:1. Removal of the isopropylidene group of 5a-f with aqueous acetic acid gave 6a-f of which oxidation with sodium periodate in the presence of a catalytic amount of potassium permanganate followed by hydrolysis with sodium hydroxide afforded the hydroxy acids 8a-f. These compounds 8a-f are useful for synthesis of renin inhibitors because the amino group of 1 and its analogues is protected as the azide group. Catalytic hydrogenation of 8a-f by palladium on carbon gave 1 and its analogues 9b-f.<sup>11)</sup>




Yields (%):

3a 83, b 84, c 88, d 80, e 93, f 93; 4a 82, b 98, c 90, d 90, e 100, f 82;  
5a 82, b 88, c 97, d 91, e 79, f 100; 6a 80, b 91, c 92, d 92, e 79, f 82;  
7a 89, b 98, c 95, d 89, e 99, f 96; 8a 95, b 99, c 92, d 82, e 100, f 100;  
1 85; 9b 74, c 88, d 92, e 83, f 81.

Reagents and reaction conditions. 1)  $R^1MgBr$  (1.8 mol equiv.),  $CuI$  (0.5 mol equiv.) in THF;  $-20--15^\circ C$ , 1 h  $\rightarrow -10-0^\circ C$ , 0.5 h  $\rightarrow 0-10^\circ C$ , 0.5 h.  
 2)  $MeSO_2Cl$  (1.25 mol equiv.),  $Et_3N$  (3.5 mol equiv.) in  $CH_2Cl_2$ ;  $5^\circ C$ , 2 h.  
 3)  $NaN_3$  (4.5 mol equiv.) in DMF;  $80^\circ C$ , 40 h. 4)  $H_2O-AcOH$  (1:1, v/v);  $100^\circ C$ , 1 h. 5)  $NaIO_4$  (5 mol equiv.),  $KMnO_4$  (0.07 mol equiv.) in  $H_2O-t-BuOH$  (3:2, v/v); r.t., 2 h. 6) 1 mol  $dm^{-3}$   $NaOH$  (1.1 mol equiv.), r.t., 1.5 h. 7)  $H_2$  (760 Torr), 5% Pd on C (10 wt. %) in AcOH;  $40^\circ C$ , 2.5 h.

Scheme 1.

Synthesis of the homostatine analogues is shown in Scheme 2. Methanolysis of **5c** in the presence of sulfuric acid gave the methyl furanoside **10** as a mixture of  $\alpha$  and  $\beta$  anomers in a ratio of 1:11. Deoxygenation of **10** was carried out by Barton's procedure<sup>12)</sup> via the dithiocarbonates **11** to give **12**. Hydrolysis of **12** in aqueous acetic acid followed by oxidation with pyridinium chlorochromate in the presence of a molecular sieve 3A<sup>13)</sup> gave the azido- $\gamma$ -lactone **14**<sup>14)</sup> which is a key intermediate of the renin inhibitor having the homostatine unit. Catalytic hydrogenation of **12** by palladium on carbon gave the amine **15** of which the amino group was protected by phthaloyl or benzyloxycarbonyl groups to afford **16a,b**. Conversion of **16a,b** to the  $\gamma$ -lactones **18a,b**<sup>14)</sup> was achieved by the same procedure described in the preparation of **14** from **12**. The lactones **18a,b** are precursors of the hydroxymethylene isostere<sup>15)</sup> of cyclohexylalanylvaline.<sup>7)</sup>



Phth = Phthaloyl; Z = Benzyloxycarbonyl

Reagents and reaction conditions. 1) concd. H<sub>2</sub>SO<sub>4</sub> (1 mol equiv.) in MeOH; r.t., 2 h. 2) i) 55% NaH (1.3 mol equiv.), CS<sub>2</sub> (1.5 mol equiv.), imidazole (0.05 mol equiv.) in THF; 5 °C, 1 h. ii) MeI (1.5 mol equiv.); 5 °C, 1 h. 3) n-Bu<sub>3</sub>SnH (1.25 mol equiv.), AIBN (0.05 mol equiv.) in toluene; 100 °C, 15 min. 4) H<sub>2</sub>O-AcOH (1:1, v/v), 100 °C, 2 h. 5) PCC (1.4 mol equiv.), powdered molecular sieve 3A in CH<sub>2</sub>Cl<sub>2</sub>, r.t., 2 h. 6) H<sub>2</sub> (760 Torr), 5 % Pd/C (10 wt. %) in EtOH; r.t., 12 h. 7) Ethoxycarbonylphthalimide (1.5 mol equiv.), NaHCO<sub>3</sub> (4 mol equiv.) in H<sub>2</sub>O-DMF (1:2, v/v); 70 °C, 2 h or N-(benzyloxycarbonyloxy)succinimide (1.1 mol equiv.), Et<sub>3</sub>N (1.1 mol equiv.) in CH<sub>2</sub>Cl<sub>2</sub>; r.t., 16 h.

Scheme 2.

## References

- 1) H. Umezawa, T. Aoyagi, H. Morishima, M. Matsuzaki, M. Hamada, and T. Takeuchi, *J. Antibiot.*, **23**, 259 (1970).
- 2) J. Marcinišzyan, J. A. Hartsuck, and J. Tang, *J. Biol. Chem.*, **251**, 7088 (1976); D. H. Rich, *J. Med. Chem.*, **28**, 263 (1985).
- 3) J. Boger, N. S. Lohr, E. H. Ulm, M. Poe, E. H. Blaine, G. M. Fenelli, T.-Y. Lin, L. S. Payne, T. W. Schorn, B. I. Lamont, T. C. Vassil, I. I. Stabilito, D. F. Veber, D. H. Rich, and A. S. Bopari, *Nature*, **303**, 81 (1983).
- 4) J. Boger, L. S. Payne, D. S. Perlow, N. S. Lohr, M. Poe, E. H. Blaine, E. H. Ulm, T. W. Schorn, B. I. LaMont, T.-Y. Lin, M. Kawai, D. H. Rich, and D. F. Veber, *J. Med. Chem.*, **28**, 1779 (1985).
- 5) H. L. Sham, C. A. Rempel, H. Stein, and J. Cohn, *Chem. Commun.*, **1987**, 683.
- 6) D. H. Rich, F. G. Salituro, and M. W. Holladay, *Proc. Am. Pept. Symp.*, 8th **1983**, 511; M. Szelke, D. M. Jones, B. Atrash, A. Hallet, and B. J. Leckie *ibid.*, **1983**, 579; M. W. Halladay, F. G. Salituro, and D. H. Rich, *J. Med. Chem.*, **30**, 374 (1987).
- 7) P. Bühlmayer, A. Caselli, W. Fuhrer, R. Göschke, V. Rasetti, H. Rüeger, J. L. Stanton, L. Criscione, and J. M. Wood, *J. Med. Chem.*, **31**, 1839 (1988).
- 8) See Ref. 3 of T. Nishi, M. Kitamura, T. Ohkuma, and R. Noyori, *Tetrahedron Lett.*, **29**, 6327 (1988).
- 9) M. Kinoshita, A. Hagiwara, and S. Aburaki, *Bull. Chem. Soc. Jpn.*, **48**, 570 (1975).
- 10) P. Szabó and L. Szabó, *J. Chem. Soc.*, **1964**, 5139.
- 11) Melting points and  $[\alpha]_D$  measured at a 1% solution in 1 mol dm<sup>-3</sup> HCl at 25 °C : **1**, 211 °C (dec), -27.7 ° ; **9b**, 228 °C, -23.8 ° ; **9c**, 230-231 °C (dec), -26.2 ° ; **9d**, 209-211 °C (dec), -21.5 ° ; **9e**, 200-202 °C, -11.4 ° ; **9f**, 221-222 °C, -15.0 ° .
- 12) D. H. R. Barton and S. W. McCombie, *J. Chem. Soc., Perkin Trans.*, **1**, **1975**, 1574.
- 13) J. Herscovici, M.-J. Egron, and K. Antonakis, *J. Chem. Soc., Perkin Trans.*, **1**, **1982**, 1967.
- 14) Melting points and  $[\alpha]_D$  at a 1% solution in CHCl<sub>3</sub>: **14**, liq., +31.8 ° ; **18a**, 139 °C, +22.7 ° ; **18b**, 107-109 °C, -35.3 ° .
- 15) T. Nishi, M. Kataoka, and Y. Morisawa, *Tetrahedron Lett.*, submitted.

(Received January 27, 1989)